Development asset linked to BeiGene in public FDA and regional records.
pharma · Advanced or metastatic solid tumors · Waldenström's Macroglobulinemia
BeiGene
BeiGene drug portfolio — 19 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
55 Cambridge Parkway, Suite 700W, Cambridge, MA 02142, US HQ
2010 Founded
2,047 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 55 Cambridge Parkway, Suite 700W, Cambridge, MA 02142, US
- Founded
- 2010
- Employees
- 2,047
- Programs
- 14
- Drugs
- 19
- Patents
- 25
BeiGene pipeline
Portfolio lens on 19 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
BeiGene drug portfolio — 19 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to BeiGene in public FDA and regional records.
-
Development asset linked to BeiGene in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to BeiGene in public FDA and regional records.
-
Development asset linked to BeiGene in public FDA and regional records.
-
Development asset linked to BeiGene in public FDA and regional records.
-
Development asset linked to BeiGene in public FDA and regional records.
-
Development asset linked to BeiGene in public FDA and regional records.
-
Development asset linked to BeiGene in public FDA and regional records.
-
obinutuzumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
Development asset linked to BeiGene in public FDA and regional records. Molecular target: T-cell immunoreceptor with Ig and ITIM domains.
- Target
- T-cell immunoreceptor with Ig and ITIM domains
- Mechanism
- T-cell immunoreceptor with Ig and ITIM domains inhibitor
-
Development asset linked to BeiGene in public FDA and regional records. Molecular target: Poly [ADP-ribose] polymerase 2.
- Target
- Poly [ADP-ribose] polymerase 2
- Mechanism
- Poly [ADP-ribose] polymerase 2 inhibitor
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to BeiGene in public FDA and regional records.
-
Development asset linked to BeiGene in public FDA and regional records.
-
Development asset linked to BeiGene in public FDA and regional records.
-
tislelizumab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in BeiGene's portfolio. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
zanubrutinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.
- Target
- Tyrosine-protein kinase BTK
- Mechanism
- Tyrosine-protein kinase BTK inhibitor